A novel, disruptive vaccination technology

Preclinical Evaluation of TriMix and Antigen mRNA-Based Antitumor Therapy

(2012) S. Van Lint et al.   CANCER RESEARCH

Cracking Open Window of Opportunity Trials

(2012) Kevin Kalinsky et al.   JOURNAL OF CLINICAL ONCOLOGY

Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect

(2012) Mariola Fotin-Mleczek et al.   JOURNAL OF GENE MEDICINE

Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection

(2012) Benjamin Petsch et al.   NATURE BIOTECHNOLOGY

Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival

(2012) Steffen Walter et al.   NATURE MEDICINE

Developing mRNA-vaccine technologies

(2012) Thomas Schlake et al.   RNA Biology

RNA-based vaccines

(2012) Jeffrey B. Ulmer et al.   VACCINE

FLT3 Ligand Enhances the Cancer Therapeutic Potency of Naked RNA Vaccines

(2011) S. Kreiter et al.   CANCER RESEARCH

Selective uptake of naked vaccine RNA by dendritic cells is driven by macropinocytosis and abrogated upon DC maturation

(2011) M Diken et al.   GENE THERAPY

Protein expression from exogenous mRNA: Uptake by receptor-mediated endocytosis and trafficking via the lysosomal pathway

(2011) Christina Lorenz et al.   RNA Biology

Determinants of intracellular RNA pharmacokinetics: Implications for RNA-based immunotherapeutics

(2011) Andreas N. Kuhn et al.   RNA Biology

Intranodal Vaccination with Naked Antigen-Encoding RNA Elicits Potent Prophylactic and Therapeutic Antitumoral Immunity

(2010) S. Kreiter et al.   CANCER RESEARCH

Messenger RNA-based Vaccines With Dual Activity Induce Balanced TLR-7 Dependent Adaptive Immune Responses and Provide Antitumor Activity

(2010) Mariola Fotin-Mleczek et al.   JOURNAL OF IMMUNOTHERAPY